AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10525751 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sulpiride
Number of subjects: 34
Study 10525751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8789975 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut allergy in siblings
Number of subjects: 622
Study 8789975 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick testing for peanut
Number of subjects: 622
Study 8789975 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of peanuts while pregnant or breastfeeding
Number of subjects: 622
Study 8789975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy prevalence in generations
Number of subjects: 622
Study 8789975 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of onset of peanut allergy
Number of subjects: 622
Study 1807738 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive PlanAlyzer cases in anemia
Number of subjects: 328
Study 1807738 — intervention group
Group type: COMPARATOR
Intervention: Text format content material (Control)
Number of subjects: 328
Study 1807738 — intervention group
Group type: EXPERIMENTAL
Intervention: PlanAlyzer cases in cardiology (after crossover)
Number of subjects: 328
Study 6220672 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 200 mg
Number of subjects: 14
Study 6220672 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg
Number of subjects: 14
Study 6220672 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 800 mg
Number of subjects: 14
Study 6220672 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 1200 mg
Number of subjects: 14
Study 6220672 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 1600 mg
Number of subjects: 14
Study 6220672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30017407 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HE4
Number of subjects: 373
Study 30017407 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA125
Number of subjects: 373
Study 30017407 — intervention group
Group type: EXPERIMENTAL
Intervention: ROMA index
Number of subjects: 373
Study 30017407 — intervention group
Group type: EXPERIMENTAL
Intervention: ROMA and HE4
Number of subjects: 373
Study 30017407 — intervention group
Group type: COMPARATOR
Intervention: CA125
Number of subjects: 373
Study 30072173 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Group (daily listening to experiential/traditional music)
Number of subjects: 65
Study 30072173 — intervention group
Group type: COMPARATOR
Intervention: Control Group (standard care only, no music therapy)
Number of subjects: 65
Study 26911380 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg/day)
Number of subjects: 279
Study 26911380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 26911380 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 279
Study 25193990 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 1867
Study 22269509 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking on the phone
Number of subjects: 138
Study 22269509 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting
Number of subjects: 138
Study 22269509 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 138
Study 22269509 — intervention group
Group type: COMPARATOR
Intervention: Undistracted
Number of subjects: 138
Study 19126248 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 19126248 — intervention group
Group type: COMPARATOR
Intervention: Dental devices
Number of subjects: 0
Study 19126248 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle advice
Number of subjects: 0
Study 17903649 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without multiple cardiac risks (N = 2314)
Number of subjects: 4414
Study 17903649 — intervention group
Group type: COMPARATOR
Intervention: Remaining excluded patients (N = 2100)
Number of subjects: 4414
Study 17903649 — intervention group
Group type: COMPARATOR
Intervention: Randomized cohort (N = 462)
Number of subjects: 4414
Study 15225081 — intervention group
Group type: EXPERIMENTAL
Intervention: Live modeling
Number of subjects: 40
Study 15225081 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected-error videotape
Number of subjects: 40
Study 15225081 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-free videotape
Number of subjects: 40
Study 15225081 — intervention group
Group type: COMPARATOR
Intervention: Handout alone
Number of subjects: 40
Study 12560588 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 0
Study 12560588 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0
Study 12560588 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-drug)
Number of subjects: 0
Study 9640973 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 32
Study 10138581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase with dosage interval adjustment recommendations by staff pharmacists
Number of subjects: 0
Study 10138581 — intervention group
Group type: COMPARATOR
Intervention: Baseline phase without dosage interval adjustment
Number of subjects: 0
Study 2750685 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystalline complex ferric orthophosphate (CFOP) labeled with 59Fe
Number of subjects: 0
Study 2750685 — intervention group
Group type: COMPARATOR
Intervention: Native Fe labeled with 55FeCl3
Number of subjects: 0
Study 998534 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated diet with added cholesterol (291 mg)
Number of subjects: 12
Study 998534 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated diet with added cholesterol (291 mg)
Number of subjects: 12
Study 998534 — intervention group
Group type: COMPARATOR
Intervention: Saturated diet without added cholesterol
Number of subjects: 12
Study 998534 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated diet without added cholesterol
Number of subjects: 12
Study 29991034 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake in infants (European CHOP Study)
Number of subjects: 0
Study 29991034 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted improvement in nutrient supply during pregnancy and infancy
Number of subjects: 0
Study 29991034 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant plasma AA and growth factors
Number of subjects: 0
Study 27681865 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (cCRTX)
Number of subjects: 175
Study 27681865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in TP53
Number of subjects: 175
Study 27681865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutated NOTCH1 and two functional KDR germline variants (rs2305948, rs1870377)
Number of subjects: 175
Study 27681865 — intervention group
Group type: EXPERIMENTAL
Intervention: All genetic markers (TP53, NOTCH1, KDR)
Number of subjects: 175
Study 27681865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in PI3K and RTK signaling pathways
Number of subjects: 175
Study 25826770 — intervention group
Group type: COMPARATOR
Intervention: Continuous Energy Restriction (CER)
Number of subjects: 45
Study 25826770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction (IER)
Number of subjects: 45
Study 22980386 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal education
Number of subjects: 477
Study 22980386 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal education
Number of subjects: 477
Study 20819508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dachengqi decoction
Number of subjects: 40
Study 18179368 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine solution
Number of subjects: 207
Study 18179368 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 207
Study 16513369 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0
Study 16513369 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12740532 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 0
Study 12740532 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 0
Study 12740532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10994885 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) at a dose of 0.1 mg/kg for 29 days
Number of subjects: 9
Study 10994885 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 9
Study 10994885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8851268 — intervention group
Group type: EXPERIMENTAL
Intervention: Taprostene administered as a continuous intravenous infusion from 2 hours before until 8 or 24 hours after angioplasty.
Number of subjects: 19
Study 8851268 — intervention group
Group type: COMPARATOR
Intervention: Control group received a combination of 330 mg aspirin and 75 mg dipyridamole.
Number of subjects: 19
Study 8851268 — intervention group
Group type: EXPERIMENTAL
Intervention: Taprostene patients experienced 3 early reocclusions up to 72 hours after the procedure and 1 late reocclusion within 3 months.
Number of subjects: 19
Study 8851268 — intervention group
Group type: COMPARATOR
Intervention: Control group (aspirin and dipyridamole).
Number of subjects: 19
Study 10147024 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 0
Study 10147024 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside/antianaerobe combination regimens
Number of subjects: 0
Study 6337200 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (10 gr twice daily)
Number of subjects: 10
Study 6337200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30470592 — intervention group
Group type: EXPERIMENTAL
Intervention: WHELD intervention
Number of subjects: 549
Study 30470592 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 549
Study 29651981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 200 mg/day, or up to 400 mg/day for women on combined oral contraceptives)
Number of subjects: 276
Study 29651981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 29651981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 276
Study 27302207 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic Eye Movement (SEM)
Number of subjects: 104
Study 27302207 — intervention group
Group type: COMPARATOR
Intervention: Pursuit Eye Movement (PEM)
Number of subjects: 104
Study 24739593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin (combination therapy)
Number of subjects: 574
Study 24739593 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (monotherapy)
Number of subjects: 574
Study 19837920 — intervention group
Group type: EXPERIMENTAL
Intervention: ID fat infusion with orlistat
Number of subjects: 34
Study 19837920 — intervention group
Group type: EXPERIMENTAL
Intervention: ID sodium oleate (C18:1)
Number of subjects: 34
Study 19837920 — intervention group
Group type: COMPARATOR
Intervention: ID sodium caprylate (C8:0)
Number of subjects: 34
Study 19837920 — intervention group
Group type: EXPERIMENTAL
Intervention: ID sodium oleate with dexloxiglumide
Number of subjects: 34
Study 19837920 — intervention group
Group type: EXPERIMENTAL
Intervention: ID fat or sodium oleate
Number of subjects: 34
Study 19837920 — intervention group
Group type: COMPARATOR
Intervention: ID sodium caprylate
Number of subjects: 34
Study 17389559 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch
Number of subjects: 34
Study 17389559 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive
Number of subjects: 34
Study 16270634 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FXIII A2 (rFXIII) at doses of 10 or 25 U/kg
Number of subjects: 24
Study 16270634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11801583 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 4 mg/kg/day
Number of subjects: 312
Study 11801583 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin
Number of subjects: 312
Study 11801583 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome)
Number of subjects: 312
Study 9973872 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg's Scale
Number of subjects: 20
Study 9973872 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale
Number of subjects: 20
Study 9973872 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Part Discomfort Rating
Number of subjects: 20
Study 7754475 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (Mynocine) 100 mg per day
Number of subjects: 124
Study 7754475 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin (Rulid) 300 mg per day
Number of subjects: 124
Study 2407004 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at various dosages (40 mg/m2, 80 mg/m2, 120 mg/m2, 180 mg/m2, 220 mg/m2)
Number of subjects: 34
Study 2407004 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) alone
Number of subjects: 34
Study 2407004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue use of 15-deoxyspergualin (DSG)
Number of subjects: 34
Study 2407004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of 15-deoxyspergualin (DSG) with other agents
Number of subjects: 34
Study 7426191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 14
Study 7426191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30655198 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (group SUX) for intubation with no further NMB administered
Number of subjects: 100
Study 30655198 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium (group CIS) for intubation and maintenance NMB
Number of subjects: 100
Study 30655198 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (group SUX)
Number of subjects: 100
Study 30655198 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium (group CIS)
Number of subjects: 100
Study 27890344 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe@Last program
Number of subjects: 1177
Study 27890344 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 1177
Study 26717354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargassum extract 250 μg/mL
Number of subjects: 11
Study 26717354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargassum extract 500 μg/mL
Number of subjects: 11
Study 26717354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Sargassum extract)
Number of subjects: 11
Study 24050803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil
Number of subjects: 7447
Study 24050803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 7447
Study 24050803 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-fat diet education)
Number of subjects: 7447
Study 20574413 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training program (work:rest ratio of 1:1, 8 weeks, 45-60 minutes, 60-79% heart rate maximum)
Number of subjects: 357
Study 20574413 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training program (8 weeks, 45-60 minutes, 60-79% heart rate maximum)
Number of subjects: 357
Study 20574413 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary during the 8 weeks)
Number of subjects: 357
Study 19639620 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,550 nm Er:Glass fractional laser (3 treatments with 6-week intervals)
Number of subjects: 20
Study 19639620 — intervention group
Group type: COMPARATOR
Intervention: CROSS method (2 treatments every 12 weeks)
Number of subjects: 20
Study 19639620 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,550 nm Er:Glass fractional laser
Number of subjects: 20
Study 19639620 — intervention group
Group type: COMPARATOR
Intervention: CROSS method
Number of subjects: 20
Study 17967602 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates
Number of subjects: 36489
Study 15281539 — intervention group
Group type: EXPERIMENTAL
Intervention: FNB and selective ONB (Group 2)
Number of subjects: 90
Study 15281539 — intervention group
Group type: EXPERIMENTAL
Intervention: FNB (Group 1)
Number of subjects: 90
Study 15281539 — intervention group
Group type: COMPARATOR
Intervention: Placebo FNB (Group 3)
Number of subjects: 90
Study 11903417 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg glimepiride
Number of subjects: 2224
Study 11903417 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glimepiride
Number of subjects: 2224
Study 11903417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2224
Study 9446434 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin
Number of subjects: 119
Study 9446434 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin
Number of subjects: 119
Study 8432776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alpha human atrial natriuretic peptide (ANP) infusion (2.5 pmol/kg.min)
Number of subjects: 8
Study 8432776 — intervention group
Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 8
Study 3481429 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate conjugated Dermatophagoides pteronyssinus extract
Number of subjects: 0
Study 3481429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29212825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (SBP target <120 mmHg)
Number of subjects: 14094
Study 29212825 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure lowering (SBP target <140 mmHg)
Number of subjects: 14094
Study 27426932 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.44 mg total macular carotenoid
Number of subjects: 28
Study 27426932 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.13 mg total macular carotenoid
Number of subjects: 28
Study 27426932 — intervention group
Group type: EXPERIMENTAL
Intervention: 27.03 mg total macular carotenoid
Number of subjects: 28
Study 27426932 — intervention group
Group type: COMPARATOR
Intervention: Placebo (safflower oil)
Number of subjects: 28
Study 24827969 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human bone morphogenetic protein‐7 (rhBMP‐7) along with intramedullary Kirschner (K)‐wire fixation and autologous bone grafting
Number of subjects: 20
Study 24827969 — intervention group
Group type: COMPARATOR
Intervention: K wire and grafting
Number of subjects: 20
Study 24827969 — intervention group
Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 20
Study 22606862 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 days horizontal bed rest
Number of subjects: 10
Study 20155235 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental schools (Tier 1 Program of Project P.A.T.H.S.)
Number of subjects: 6785
Study 20155235 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 6785
Study 17650364 — intervention group
Group type: EXPERIMENTAL
Intervention: Process simulation only
Number of subjects: 146
Study 17650364 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome simulation only
Number of subjects: 146
Study 17650364 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-plus-outcome simulation
Number of subjects: 146
Study 17650364 — intervention group
Group type: COMPARATOR
Intervention: Distractor control condition
Number of subjects: 146
Study 16622454 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 80 mg m‐2 and epirubicin 75 mg m‐2 (ED)
Number of subjects: 51
Study 16622454 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 100 mg m‐2 (D)
Number of subjects: 51
Study 12955305 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone
Number of subjects: 18
Study 12955305 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oxycodone
Number of subjects: 18
Study 12955305 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oxycodone
Number of subjects: 18
Study 12955305 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg morphine
Number of subjects: 18
Study 12955305 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 18
Study 12955305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11763004 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg daily for 6 weeks)
Number of subjects: 18
Study 11763004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study 8989002 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.1 mg/kg bolus followed by 1 mg.kg-1.h-1 continuous infusion)
Number of subjects: 60
Study 8989002 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (placebo)
Number of subjects: 60
Study 8433358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive distraction
Number of subjects: 60
Study 8433358 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 60
Study 8433358 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 60
Study 2887529 — intervention group
Group type: EXPERIMENTAL
Intervention: mesterolone
Number of subjects: 40
Study 2887529 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 31538405 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal epidural injection of 1 mL 0.5% bupivacaine with 3 cycles of pulsed radiofrequency of the DRG for 180 seconds (LPRF group)
Number of subjects: 50
Study 31538405 — intervention group
Group type: COMPARATOR
Intervention: Transforaminal epidural injection of 1 mL 0.5% bupivacaine (LA group)
Number of subjects: 50
Study 29309313 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated mechanical peripheral stimulation (AMPS) applied twice a week for 4 weeks using a commercial medical device (Gondola) delivering mechanical pressure in four areas of feet.
Number of subjects: 30